Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli ...
Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...
Basel, 31 January 2025 - Roche ... PATHWAY HER2 (4B5) test was used as part of the DESTINY-Breast06 trial, which showed a median progression-free survival of 13.2 months with ENHERTU compared to 8 ...
Basel, 31 January 2025 - Roche (SIX ... tissue samples. The PATHWAY HER2 (4B5) test was used as part of the DESTINY-Breast06 trial, which showed a median progression-free survival of 13.2 months with ...
[Operator Instructions] One last remark, if you would like to follow the presented slides on your end as well, please feel free to go to ... CHF1.1 billion more taxes than last year. Part of ...
With the introduction of HER2-low and now HER2-ultralow classifications, Roche ... PATHWAY HER2 (4B5) test was used as part of the DESTINY-Breast06 trial, which showed a median progression-free ...
(PRESS RELEASE) BASEL, 1-Feb-2025 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label for its PATHWAY® anti ...
Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback